Continuous Glucose Monitoring in Insulin-Treated Older Adults With Diabetes and Alzheimer Disease and Related Dementias

Is the use of continuous glucose monitoring (CGM) associated with improved glycemic outcomes and related adverse events in insulin-treated older adults with Alzheimer disease and related dementias (ADRD) and diabetes?This cohort study of 1011 CGM users and 1011 prevalent SMBG users who were propensity score–matched found that CGM use was associated with a significantly lower risk of all-cause hospitalization and all-cause mortality, while associations with glycemic outcomes varied.This study highlights the potential long-term benefits of CGM in insulin-treated older adults with diabetes and ADRD and the need for clinical trials in this population.

Corresponding Author: Jingchuan Guo, MD, PhD, Department of Pharmaceutical Outcomes and Policy, University of Florida, College of Pharmacy, 1889 Museum Rd, Gainesville, FL 32606 (guoj1@ufl.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.